About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The Company's DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. It also focuses on development program for COL 195, an abuse deterrent, extended release hydrocodone for the treatment of chronic pain. It is focusing on COL 171, a preclinical DETERx extended release, abuse deterrent methylphenidate formulation for the treatment of ADHD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: COLL
- Previous Close: $14.04
- 50 Day Moving Average: $15.51
- 200 Day Moving Average: $14.92
- 52-Week Range: $8.24 - $20.55
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.62
- P/E Growth: 0.00
- Market Cap: $329.38M
- Outstanding Shares: 23,460,000
- Beta: 0.25
- Return on Equity: -80.20%
- Return on Assets: -67.31%
Companies Related to Collegium Pharmaceutical:
- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 4.29%
- Quick Ratio: 4.22%
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?
5 analysts have issued 1 year target prices for Collegium Pharmaceutical's stock. Their forecasts range from $23.00 to $30.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $25.40 in the next year.
When will Collegium Pharmaceutical announce their earnings?
Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Collegium Pharmaceutical stock?
Collegium Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.86%), Frazier Management LLC (8.04%), Franklin Resources Inc. (7.66%), FMR LLC (3.90%), Highland Capital Management LP (2.92%) and State Street Corp (1.23%). Company insiders that own Collegium Pharmaceutical stock include John A Fallon, John Gordon Freund and Longitude Capital Partners, Ll.
Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?
Collegium Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Highland Capital Management LP, Perceptive Advisors LLC, FMR LLC, J. Goldman & Co LP, State Street Corp and Eventide Asset Management LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon, John Gordon Freund and Longitude Capital Partners, Ll.
How do I buy Collegium Pharmaceutical stock?
Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Collegium Pharmaceutical stock cost?
One share of Collegium Pharmaceutical stock can currently be purchased for approximately $14.04.